Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 5/20 | 0.42 |
| ▸ | MIF | P14174 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 6/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.35 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5386267 | 0.81 | ESR1 (0.53) | ESR2ESR1 | |
| SCHEMBL5380495 | 0.74 | ESR2 (0.44) | ESR2MIFAPP | |
| Mequinol SCHEMBL10605062 | 0.66 | ESR2 (0.70) | ESR2APPESR1LTA4HCALM1 | |
| SCHEMBL5382273 | 0.64 | HTR2C (0.43) | ESR2MAOAMAOBLTA4HCALM1 | |
| SCHEMBL1341494 | 0.64 | ESR2 (1.00) | ESR2APPESR1LTA4HCALM1 | |
| SCHEMBL15599404 | 0.64 | ESR2 (1.00) | ESR2APPESR1LTA4HCALM1 | |
| Mequinol SCHEMBL28122193 | 0.62 | LTA4H (0.64) | ESR2APPESR1LTA4HCALM1 | |
| Mequinol SCHEMBL481721 | 0.62 | LTA4H (0.70) | ESR2APPESR1LTA4HCALM1 | |
| SCHEMBL28162733 | 0.62 | ESR2 (0.95) | ESR2APPESR1LTA4HCALM1 | |
| Mequinol SCHEMBL21009 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142379-A1 | CYCLOHEXYL DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | JAIN NARESHKUMAR F | 2007-06-21 | — | — | US | disclosed |
| US-20070142379-A1 | CYCLOHEXYL DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | JAIN NARESHKUMAR F | 2007-06-21 | — | — | US | disclosed |
| US-20070142379-A1 | CYCLOHEXYL DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | JAIN NARESHKUMAR F | 2007-06-21 | — | — | US | disclosed |
| US-7183445-B2 | Cyclohexyl derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V (BE) | 2007-02-27 | — | — | US | disclosed |
| US-7183445-B2 | Cyclohexyl derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V (BE) | 2007-02-27 | — | — | US | disclosed |
| US-7183445-B2 | Cyclohexyl derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V (BE) | 2007-02-27 | — | — | US | disclosed |
| US-20050009799-A1 | Cyclohexyl derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009799-A1 | Cyclohexyl derivatives as selective estrogen receptor modulators | ESR2, GPER1, ESR1 | ESR2 1/4885MIF 3775/4885APP 2950/4885 |
| US-20070142379-A1 | CYCLOHEXYL DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | ESR2, GPER1, ESR1 | ESR2 1/4885MIF 3775/4885APP 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.